

company announcement

Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 2 May 2019 – On 1 February 2019, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR), also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 1 February 2019.

Under the programme initiated 1 February 2019, Novo Nordisk will repurchase B shares for an amount up to DKK 2.7 billion in the period from 1 February 2019 to 1 May 2019. The programme is now concluded.

Since the announcement as of 29 April 2019, the following transactions have been made under the programme:

	Number of B shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	7,745,980		2,562,505,583
29 April 2019	140,000	331.37	46,391,131
30 April 2019	150,000	328.90	49,334,596
1 May 2019	128,024	326.25	41,768,416
Accumulated under the programme	8,164,004		2,699,999,726

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

With the transactions stated above, Novo Nordisk owns a total of 15,356,501 B shares of DKK 0.20, corresponding to 0.6% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,400,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 1 February 2019. As of 1 May 2019, Novo Nordisk has since 1 February 2019 repurchased a total of 8,164,004 B shares at an average share price of DKK 330.72 per B share equal to a transaction value of DKK 2,699,999,726.

Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 43,200 people in 80 countries and markets its products in more than 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, [Facebook](#), [Twitter](#), [LinkedIn](#), [YouTube](#).

Further information

Media:

Anne Margrethe Hauge	+45 4442 3450	amhg@novonordisk.com
Ken Inchausti (US)	+1 609 240 9429	kiau@novonordisk.com

Investors:

Peter Hugrefte Ankersen	+45 3075 9085	phak@novonordisk.com
Valdemar Borum Svarrer	+45 3079 0301	jvls@novonordisk.com
Ann Søndermølle Rendbæk	+45 3075 2253	arnd@novonordisk.com
Kristoffer Due Berg (US)	+1 609 235 2989	krdb@novonordisk.com